INFI - Infinity Pharmaceuticals Inc. Investors: Lead Plaintiff Deadline is Approaching in the Class Action Against Infinity Pharmaceuticals Inc.; Contact Robbins LLP Today | Benzinga
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) securities between January 5, 2023 and July 24, 2023. Infinity is a clinical-stage biopharmaceutical company focusing on developing novel medicines for people with cancer.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: Infinity Pharmaceuticals, Inc. (INFI) Misled Investors Regarding its Business Prospects
According to the complaint, for over a year, defendants pushed the false narrative that Infinity's flagship product, eganelisib, was proceeding apace in its clinical studies as a treatment for breast cancer. Results were initially so promising that partners were being sought (and prospective partners were interested) to bring eganelisib to the next stage. Then, ...